Connor, Clark & Lunn Investment Management Ltd. Tricida, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$7.31 - $11.85 $189,314 - $306,891	-25,898 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$7.35 - $10.63 $332,925 - $481,496	-45,296 Reduced 63.62%	25,898 $213,000
Q4 2021 Feb 10, 2022	SELL	$4.19 - $9.56 $167,101 - $381,262	-39,881 Reduced 35.9%	71,194 $681,000
Q3 2021 Nov 12, 2021	SELL	$3.56 - $4.64 $57,604 - $75,079	-16,181 Reduced 12.72%	111,075 $515,000
Q2 2021 Aug 12, 2021	BUY	$3.95 - $5.41 $255,079 - $349,361	64,577 Added 103.03%	127,256 $550,000
Q1 2021 May 13, 2021	BUY	$4.52 - $7.8 $283,309 - $488,896	62,679 New	62,679 $332,000

Others Institutions Holding TCDA

# of Institutions

Shares Held

30K

Call Options Held

124K

Put Options Held

46.5K

View Full List

About Tricida, Inc.

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

More about TCDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account